Century Therapeutics, Inc.

NASDAQ:IPSC

Biotechnology

Healthcare
$1.38 +0.48%

+$0.01 today

Market cap
$250.60M
Beta
1.57
P/E (TTM)
-1.8
EPS (TTM)
-$1.25
52W Low $0.44High $3.04

Volume 1.14M

Average 1.12M

IPSC Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Century Therapeutics, Inc.NASDAQ: IPSC

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $0 a year earlier. Trailing-twelve-month income tax expense was -$68K.

Context

  • Income tax expense amounted to 0.1% of revenue in FY2025, down 27.1 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$17K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$68K-103.8% YoY
LTMMar 2026
-$68K-103.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-103.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(68K) USD
Year-over-year change
-103.8%

Income Tax Expense vs competitors

How IPSC compares with its peers on the latest reported figures

  • IPSC's LTM Mar 2026 income tax expense of -$68K is the 7th highest of the 8 companies compared; the peer median is $0.
  • Its year-over-year change of -103.8% is the 3rd highest of 4, against a peer median of -100.0%.
IPSC Competitors Peer median
Income Tax Expense for IPSC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CUECue Biopharma, Inc.LTM Mar 2026$500K ——1.5%
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$8K -63.6%-51.2%0.0%
EQEquillium, Inc.LTM Mar 2026$0 -100.0%——
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
OSTXOS Therapies IncorporatedLTM Mar 2026$0 ———
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$68K -103.8%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.55M -55622.5%—466.7%
Peer median (excluding IPSC) $0-100.0%-51.2%0.8%

Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue05.2M2.24M6.59M109.16M
Cost of Revenue4.58M00013.1M
Gross Profit(4.58M)5.2M2.24M6.59M96.06M
Gross Margin—100.0%100.0%100.0%88.0%
Research & Development75.65M97.17M92.71M107.24M95.67M
Selling, General & Admin14.65M31.86M34.71M33.16M24M
Operating Expenses90.3M139.03M148.78M144.73M111.1M
Depreciation & Amortization4.58M8.44M13.04M13.3M13.1M
EBITDA(89.92M)(121.2M)(121.21M)(111.47M)3.45M
EBITDA Margin—-2331.2%-5423.2%-1691.8%3.2%
Operating Income(94.88M)(133.83M)(146.55M)(138.14M)(15.04M)
Operating Margin—-2574.2%-6556.9%-2096.5%-13.8%
Interest Income898K2.99M12.68M13.01M7.35M
Interest Expense1.28M0540K00
Other Income / Expenses(898K)2.99M11.75M13.36M5.39M
Income Before Tax(95.78M)(130.84M)(134.79M)(124.78M)(9.65M)
Pre-Tax Margin—-2516.7%-6031.0%-1893.7%-8.8%
Income Tax Expense43K91K1.88M1.79M(68K)
Net Income(95.82M)(130.93M)(136.67M)(126.57M)(9.58M)
Net Margin—-2518.4%-6115.1%-1920.9%-8.8%
EPS (Basic)(1.74)(2.27)(2.30)(1.61)(0.11)
EPS (Diluted)(1.74)(2.27)(2.30)(1.61)(0.11)
Weighted Avg Shares55.01M57.76M59.31M78.65M86.56M
Weighted Avg Shares (Diluted)55.01M57.76M59.31M78.65M86.56M

Century Therapeutics, Inc.

NASDAQ:IPSC

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.